Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia

References

• Glickman M., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of constitution. Physiol Rev 2002;82:373–428.
   PubMed Web of Science ®Google Scholar
• Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC class I - mediated antigen presentation. Curr Opin Immunol 2004;16:76–81.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739–58.
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002;14:628–34.
   PubMed Web of Science ®Google Scholar
• Almond JB, Cohen G. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433–43.
   PubMed Web of Science ®Google Scholar
• Orlowski Z. The ubiquitin proteasome pathway from bench to beside. Hematology 2005;1:220–5.
   Google Scholar
• Nencioni A, Grünebach F, Patrone F, Ballestrero A., Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30–6.
   PubMed Web of Science ®Google Scholar
• Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;7:1836–43.
   Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 2007;110:3281–90.
   PubMed Web of Science ®Google Scholar
• Parlati F, Lee S, Aujay M,Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD. Carfilzomib can induce cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114:3439–47.
   PubMed Web of Science ®Google Scholar
• Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O. The proteasome inhibitors bortezomib and PF-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukemia cells. Br J Haematol 2007;136:814–28.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005;8:407–19.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell A.T, Sridhada R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955–60.
   PubMed Web of Science ®Google Scholar
• Vink J, Cloos J, Kaspers GJL. Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol 2006;134:253–62.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371–6.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005;104:1794–807.
   PubMed Web of Science ®Google Scholar
• Powell SR. The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 2006;291:H1–H19.
   PubMed Web of Science ®Google Scholar
• Matsuda N, Tanaka K. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease? J Alzheimers Dis 2010;19:1–9.
   PubMed Web of Science ®Google Scholar
• Koreth J, Alyea EP, Murphy WJ, Welniak LA. Proteasome inhibition and allogenic hematopoietic stem cell transplantation: a review. Biol Blood Marrow Transplant 2009;15:1502–12.
   PubMedGoogle Scholar
• Sixt SU, Dahlmann B. Extracellular, circulating proteasomes and ubiqutin – Incidence and relevance. Biochim Biophys Acta 2008;1782:817–23.
   PubMed Web of Science ®Google Scholar
• Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 1993;121:215–23.
   PubMed Web of Science ®Google Scholar
• Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF., Bureau JP . Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 2001;92:2493–500.
   PubMed Web of Science ®Google Scholar
• Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP, Ouali A. Development and evaluation of sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods 2002;260:183–93.
   PubMed Web of Science ®Google Scholar
• Jakob C, Egerer K, Liebisch P, Turkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner M, Stera J, Kleeberg L, Feist E, Burnmester GR, Kloetzel PM, Sezer O. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100–3.
   PubMed Web of Science ®Google Scholar
• Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J. Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem 2008;41:1377–83.
   PubMed Web of Science ®Google Scholar
• Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulation proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 2008;112:1306–12.
   PubMed Web of Science ®Google Scholar
• Ma W, Kantarjian H, Bekele B, Donahaue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortez J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res 2009;15:3820–6.
   PubMed Web of Science ®Google Scholar
• Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 2005;152:948–53.
   PubMed Web of Science ®Google Scholar
• Orlowski M, Wilk S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Archiv Biochem Biophys 2000;383:1–16.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method of the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54.
   PubMed Web of Science ®Google Scholar
• Kumatori A., Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, Tachikawa T, Shin S, Ichihara A. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990;87:7071–5.
   PubMed Web of Science ®Google Scholar